Pricing & Reimbursement

Pricing & Reimbursement

  • Parexel Analyzes the Real-World Data Revolution and Role of Early Payer Engagement2:21

    Parexel Analyzes the Real-World Data Revolution and Role of Early Payer Engagement

    Richard Tolley, Vice President Integrated Market Access Solutions at Parexel discusses a recent roundtable discussion about the role of early payer insights in real-world data studies.

    Watch Video
  • See how our experts can add value to your strategy

    Learn More ►
  • Get your free evidence readiness score today!

    Take Assessment
  • ×

    Speak to one of our experts today

    First Name
    Last Name
    Company Name
    Title
    Country
    Tell us how we can help
    We'll be in touch shortly!
    Error - something went wrong!
  • Innovative Pricing and Reimbursement Schemes - The Why, What, Which & How

    Innovative Pricing and Reimbursement Schemes - The Why, What, Which & How

    Learn about the need for innovation in global reimbursement mechanisms, the potential risks and benefits of implementation, and real world examples in a presentation by PAREXEL Access Consulting Exper

    View Presentation
  • The FDA Approval of Eteplirsen: Necessary Flexibility or Worrying Precedent? Poster

    The FDA Approval of Eteplirsen: Necessary Flexibility or Worrying Precedent? Poster

    Read More
  • Orphan Diseases Translating Expedited Regulatory approval into Reimbursement success article

    Orphan Diseases Translating Expedited Regulatory approval into Reimbursement success article

    View Now
  • Presentation Slides: Early Engagement Strategies Webinar

    Presentation Slides: Early Engagement Strategies Webinar

    View Now
  • The Future of UK Drug Pricing: The 2014 PPRS - An Interim Review

    The Future of UK Drug Pricing: The 2014 PPRS - An Interim Review

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

    Read More
  • Biosimilar mAbs – a unique and distinct market (for the time being…?)

    Biosimilar mAbs – a unique and distinct market (for the time being…?)

    Read More
  • CADTH's $50,000 Cost-Effectiveness Threshold: Fact or Fiction?

    CADTH's $50,000 Cost-Effectiveness Threshold: Fact or Fiction?

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017

    Read More
  • Managed Access Agreements: A New Model Pathway For Reimbursement of Non-Oncology Drugs in England Approved Under European Adaptive Pathways?

    Managed Access Agreements: A New Model Pathway For Reimbursement of Non-Oncology Drugs in England Approved Under European Adaptive Pathways?

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

    Read More
  • Could AMNOG Become Irrelevant in the 21st Century? Potential Redundancies in the AMNOG Process in the Era of Curative Therapies

    Could AMNOG Become Irrelevant in the 21st Century? Potential Redundancies in the AMNOG Process in the Era of Curative Therapies

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

    Read More
  • ×

    Tell Us About Your Market Access Nightmares.

    What keeps you up at night?
    Thank you!
    Error - something went wrong!
  • Review of Health Economic Models For Antibiotics

    Review of Health Economic Models For Antibiotics

    Educational poster presented at ISPOR 20th Annual European Congress, November 2017.

    Read More
  • loading
    Loading More...